NEW YORK--(BUSINESS WIRE)--
ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) announced today that Jonathan
Lewis, M.D., Ph.D., Chief Executive Officer, will present at the
upcoming 29th Annual J.P. Morgan Healthcare Conference on
January 13th at 2:00 pm. PST at the Westin St. Francis Hotel
in San Francisco, CA. Dr. Lewis will provide an overview of the Company
and its clinical development programs.
To access the live audio webcast, please visit the Investor Relations
section at www.ziopharm.com.
The webcast will be archived for 90 days.
About ZIOPHARM Oncology, Inc.:
ZIOPHARM Oncology is a biopharmaceutical company engaged in the
development and commercialization of a diverse portfolio of cancer
drugs. The Company is currently focused on three clinical programs.
Palifosfamide (ZymafosTM or ZIO-201) is a novel DNA
cross-linker in class with bendamustine, ifosfamide, and
cyclophosphamide. ZIOPHARM is currently enrolling patients in a
randomized, double-blinded, placebo-controlled Phase III trial with
palifosfamide administered intravenously for the treatment of metastatic
soft tissue sarcoma in the front-line setting. The Company expects to
initiate additional studies in the near-term, including a Phase I
intravenous study of palifosfamide in combination with standard of care
addressing small cell lung cancer and a Phase I study of oral
palifosfamide.
Darinaparsin (ZinaparTM or ZIO-101) is a novel
mitochondrial-targeted agent (organic arsenic) being developed
intravenously for the treatment of peripheral T-cell lymphoma with a
pivotal study expected to begin in late 2011. An oral form is in a Phase
I trial in solid tumors.
Indibulin (ZybulinTM or ZIO-301) is a novel, oral tubulin
binding agent that is expected to have several potential benefits
including oral dosing, application in multi-drug resistant tumors, no
neuropathy and minimal overall toxicity. It is currently being studied
in Phase I/II in metastatic breast cancer.
ZIOPHARM's operations are located in Boston, MA with an executive office
in New York City. Further information about ZIOPHARM may be found at www.ziopharm.com.
ZIOP-G
Forward-Looking Safe Harbor Statement:
This press release contains forward-looking statements for ZIOPHARM
Oncology, Inc. that involve risks and uncertainties that could cause the
Company's actual results to differ materially from the anticipated
results and expectations expressed in these forward-looking statements.
These statements are based on current expectations, forecasts and
assumptions that are subject to risks and uncertainties, which could
cause actual outcomes and results to differ materially from these
statements. Among other things, there can be no assurance that any of
the Company's development efforts relating to its product candidates
will be successful, or such product candidates will be successfully
commercialized. Other risks that affect forward-looking information
contained in this press release include the possibility of being unable
to obtain regulatory approval of the Company's product candidates, the
risk that the results of clinical trials may not support the Company's
claims, the risk that pre-clinical or clinical trials will proceed on
schedules that are consistent with the Company's current expectations or
at all, risks related to the Company's ability to protect its
intellectual property and its reliance on third parties to develop its
product candidates, risks related to the sufficiency of existing capital
reserves to fund continued operations for a particular amount of time
and uncertainties regarding the Company's ability to obtain additional
financing to support its operations thereafter, as well as other risks
regarding the Company that are discussed under the heading "Risk
Factors" in the Company's filings with the United States Securities and
Exchange Commission. Forward-looking statements can be identified by the
use of words such as "may," "will," "intend," " should," "could," "can,"
"would," "expect," "believe," "estimate," " predict," "potential,"
"plan," "is designed to," "target" and similar expressions. The Company
assumes no obligation to update these forward-looking statements, except
as required by law.
ZIOPHARM Oncology, Inc.
Tyler Cook, 617-259-1982
tcook@ziopharm.com
or
Media:
Argot
Partners
David Pitts, 212-600-1902
david@argotpartners.com
Source: ZIOPHARM Oncology, Inc.
News Provided by Acquire Media
